The AAI Position Statement program is designed to engage AAI members in shaping the organization’s advocacy and鈥� priorities. Through the development of these Position Statements, AAI aims to identify and articulate policy recommendations on topics of particular interest to our members and the broader immunology community. AAI will share these recommendations with appropriate audiences—including Members of Congress and federal agencies like the National Institutes of Health and the Centers for Disease Control and Prevention (CDC)—to help policymakers make informed, evidence-based decisions about federal science policy.
Read more about the program and learn about how you can get involved on the page. If you have ideas for a future position statement, please email Senior Science Policy Analyst Emily Kansler, Ph.D., at ekansler@aai.org.
Statements
April 1, 2026
This position statement describes the critical role of vaccines in protecting public health, the power of vaccines to treat both infectious and chronic diseases, and how recent concerning changes in federal vaccine policy risk health and undermine public trust. AAI urges Congress and federal agencies, in close coordination with the scientific community, to ensure evidence-based vaccine policy, strengthen public trust in vaccines, and address gaps in vaccine science knowledge.
View the vaccine policy recommendations at-a-glance
August 22, 2025
The AAI fiscal year (FY) 2026 funding recommendation for NIH. This position statement outlines NIH’s essential role in improving human health, fueling the economy, and maintaining U.S. global competitiveness and national security. AAI urges Congress to provide NIH with at least $51.3 billion and the National Institute for Allergy and Infectious Diseases with at least $7.29 billion for FY 2026.
August 22, 2025
The AAI fiscal year (FY) 2026 funding recommendation for ARPA-H. This position statement emphasizes ARPA-H’s unique mission of advancing transformative healthcare through high-risk, high reward research projects. AAI urges Congress to provide ARPA-H with at least $1.7 billion for FY 2026 and to maintain ARPA-H as an independent entity.